- Home
- PSNL vs GNTA Comparison
PSNL vs GNTA Comparison
Compare PSNL & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | GNTA |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.1M | 41.7M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PSNL | GNTA |
|---|---|---|
| Price | $8.06 | $1.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $10.71 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 106.2K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $69,103,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.83 | $1.35 |
| 52 Week High | $11.40 | $10.00 |
Technical Indicators
Market Signals| Indicator | PSNL | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 40.45 | 28.85 |
| Support Level | $9.34 | $1.80 |
| Resistance Level | $9.85 | $1.77 |
| Average True Range (ATR) | 0.62 | 0.18 |
| MACD | -0.25 | -0.02 |
| Stochastic Oscillator | 3.33 | 2.22 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.